000 03532nam a22004815i 4500
001 978-1-4614-0613-6
003 DE-He213
005 20140220083239.0
007 cr nn 008mamaa
008 110920s2012 xxu| s |||| 0|eng d
020 _a9781461406136
_9978-1-4614-0613-6
024 7 _a10.1007/978-1-4614-0613-6
_2doi
050 4 _aRC261-271
072 7 _aMJCL
_2bicssc
072 7 _aMED062000
_2bisacsh
082 0 4 _a614.5999
_223
100 1 _aTerabe, Masaki.
_eeditor.
245 1 0 _aNatural Killer T cells
_h[electronic resource] :
_bBalancing the Regulation of Tumor Immunity /
_cedited by Masaki Terabe, Jay A. Berzofsky.
250 _a1.
264 1 _aNew York, NY :
_bSpringer New York,
_c2012.
300 _aXII, 208 p.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aCancer Drug Discovery and Development
505 0 _aPreface.-  Introduction: Mechanisms of NKT cell-mediated adjuvant activity and function of iPS-derived NKT cells -- Structure and Recognition of Antigens for Invariant NKT Cells -- Invariant NKT cell-based vaccine strategies -- Immune regulation of tumor immunity by NKT cells -- The Regulation of CD1d+ and CD1d- tumors by NKT Cells -- DC-based immunotherapy targeting NKT cells -- Therapeutic Approaches Utilising NKT Cells -- NKT Cells of Cancer Patients & How Models can Inform Therapeutic Plans -- Understanding the role of Natural Killer T (NKT) cells in hematologic malignancies: progress and challenges -- Clinical trials with α-galactosylceramide (KRN7000) in advanced cancer -- Clinical trials of invariant Natural Killer T cell-based immunotherapy for cancer -- Index.  .
520 _aNatural killer T (NKT) cells are CD1d-restricted T cells that respond to lipid, not protein, antigens presented by CD1d, which is a non-classical MHC class I-like molecule.  This relatively small but pivotal T cell population bridges the gap between innate and adaptive immunity by rapidly produce large amounts of many kinds of cytokines and by providing the T cell arm of the adaptive immune system a mechanism to detect lipid antigens. NKT cells also have both regulatory and effector functions and have been shown to play critical roles in the regulation of immune responses in many disease settings including cancer. Stimulating the protective functions of NKT cells while inhibiting the negative regulatory activity shows promise for the therapy of cancer and several approaches are in clinical trials.               This book reviews what we have learned about NKT cells during last two decades through functional studies in the context of tumor immunology, including clinical trials of NKT cell targeted therapy.  This knowledge should also be informative to understand the role of this underappreciated T cell population in many other fields outside of tumor immunology.
650 0 _aMedicine.
650 0 _aOncology.
650 0 _aToxicology.
650 1 4 _aBiomedicine.
650 2 4 _aCancer Research.
650 2 4 _aPharmacology/Toxicology.
700 1 _aBerzofsky, Jay A.
_eeditor.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9781461406129
830 0 _aCancer Drug Discovery and Development
856 4 0 _uhttp://dx.doi.org/10.1007/978-1-4614-0613-6
912 _aZDB-2-SBL
999 _c100888
_d100888